Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality
Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ubiquity Press
2020-08-01
|
| Series: | Global Heart |
| Subjects: | |
| Online Access: | https://globalheartjournal.com/articles/608 |
| _version_ | 1819175311162474496 |
|---|---|
| author | Ezequiel J. Zaidel Xinyi Leng Abiodun Moshood Adeoye Ferdous Hakim Biraj Karmacharya Asim Katbeh Lis Neubeck Stephanie Partridge Pablo Perel Mark D. Huffman Mariachiara Di Cesare |
| author_facet | Ezequiel J. Zaidel Xinyi Leng Abiodun Moshood Adeoye Ferdous Hakim Biraj Karmacharya Asim Katbeh Lis Neubeck Stephanie Partridge Pablo Perel Mark D. Huffman Mariachiara Di Cesare |
| author_sort | Ezequiel J. Zaidel |
| collection | DOAJ |
| description | Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs. |
| first_indexed | 2024-12-22T20:52:51Z |
| format | Article |
| id | doaj.art-fd01ac37cf2c4eb3a5c8f3d5a5c88b0d |
| institution | Directory Open Access Journal |
| issn | 2211-8179 |
| language | English |
| last_indexed | 2024-12-22T20:52:51Z |
| publishDate | 2020-08-01 |
| publisher | Ubiquity Press |
| record_format | Article |
| series | Global Heart |
| spelling | doaj.art-fd01ac37cf2c4eb3a5c8f3d5a5c88b0d2022-12-21T18:13:03ZengUbiquity PressGlobal Heart2211-81792020-08-0115110.5334/gh.608783Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and MortalityEzequiel J. Zaidel0Xinyi Leng1Abiodun Moshood Adeoye2Ferdous Hakim3Biraj Karmacharya4Asim Katbeh5Lis Neubeck6Stephanie Partridge7Pablo Perel8Mark D. Huffman9Mariachiara Di Cesare10Cardiology Department, Sanatorio Güemes, and Pharmacology Department, School of Medicine, University of Buenos AiresDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong SARCardiovascular Unit, Department of Medicine, University College Hospital, Ibadan/College of Medicine, University of Ibadan, Ibadan; Cardiovascular Genetics and Genomic Research Unit, Institute of Cardiovascular Diseases, Faculty of Clinical Sciences, College of Medicine, University of IbadanResearch and Publication Unit, World Health OrganizationDepartment of Public Health, Public Health and Community Programs, Kathmandu University School of Medical SciencesInternational PhD Programme in Cardiovascular Pathophysiology and Therapeutics, CardioPaThSchool of Health and Social Care, Edinburgh Napier University, GB; The University of Sydney Susan Wakil School for Nursing and Midwifery, Charles Perkins Centre, SydneyWestmead Applied Research Centre, Faculty of Medicine and Health, The University of SydneyDepartment of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical MedicineNorthwestern University Feinberg School of Medicine, Departments of Preventive Medicine and Medicine and Center for Global Cardiovascular Health, Chicago, Illinois, US; The George Institute for Global Health, University of New South Wales, SydneyDepartment of Natural Science, School of Science and Technology, Middlesex University LondonNon-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.https://globalheartjournal.com/articles/608non-valvular atrial fibrillationnon-vitamin k antagonist oral anticoagulants (noacs)essential medicine liststrokeprevention |
| spellingShingle | Ezequiel J. Zaidel Xinyi Leng Abiodun Moshood Adeoye Ferdous Hakim Biraj Karmacharya Asim Katbeh Lis Neubeck Stephanie Partridge Pablo Perel Mark D. Huffman Mariachiara Di Cesare Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality Global Heart non-valvular atrial fibrillation non-vitamin k antagonist oral anticoagulants (noacs) essential medicine list stroke prevention |
| title | Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality |
| title_full | Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality |
| title_fullStr | Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality |
| title_full_unstemmed | Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality |
| title_short | Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality |
| title_sort | inclusion in the world health organization model list of essential medicines of non vitamin k anticoagulants for treatment of non valvular atrial fibrillation a step towards reducing the burden of cardiovascular morbidity and mortality |
| topic | non-valvular atrial fibrillation non-vitamin k antagonist oral anticoagulants (noacs) essential medicine list stroke prevention |
| url | https://globalheartjournal.com/articles/608 |
| work_keys_str_mv | AT ezequieljzaidel inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT xinyileng inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT abiodunmoshoodadeoye inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT ferdoushakim inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT birajkarmacharya inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT asimkatbeh inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT lisneubeck inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT stephaniepartridge inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT pabloperel inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT markdhuffman inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality AT mariachiaradicesare inclusionintheworldhealthorganizationmodellistofessentialmedicinesofnonvitaminkanticoagulantsfortreatmentofnonvalvularatrialfibrillationasteptowardsreducingtheburdenofcardiovascularmorbidityandmortality |